Umeå University's logo

umu.sePublications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
LRP8 is a receptor for tick-borne encephalitis virus
Department of Microbiology and Immunology, Albert Einstein College of Medicine, NY, New York, United States.
Department of Microbiology and Immunology, Albert Einstein College of Medicine, NY, New York, United States.
Department of Medicine Huddinge, Center for Infectious Medicine, Karolinska Institutet, Stockholm, Sweden.
United States Army Medical Research Institute of Infectious Diseases, MD, Fort Detrick, United States; The Geneva Foundation, WA, Tacoma, United States; The Henry M. Jackson Foundation, MD, Bethesda, United States.
Show others and affiliations
2025 (English)In: Nature, ISSN 0028-0836, E-ISSN 1476-4687Article in journal (Refereed) Epub ahead of print
Abstract [en]

Tick-borne encephalitis virus (TBEV) causes tick-borne encephalitis (TBE), a severe and sometimes life-threatening disease characterized by viral invasion of the central nervous system with symptoms of neuroinflammation1,2. As with other orthoflaviviruses—enveloped, arthropod-borne RNA viruses—host factors required for TBEV entry remain poorly defined. Here we used a genome-scale CRISPR–Cas9-based screen to identify LRP8, an apolipoprotein E and reelin receptor with high expression in the brain, as a TBEV receptor. LRP8 downregulation reduced TBEV infection in human cells, and its overexpression enhanced infection. LRP8 bound directly to the TBEV E glycoprotein and mediated viral attachment and internalization into cells. An LRP8-based soluble decoy blocked infection of human cell lines and neuronal cells and protected mice from lethal TBEV challenge. LRP8’s role as a TBEV receptor has implications for TBEV neuropathogenesis and the development of antiviral countermeasures.

Place, publisher, year, edition, pages
Springer Nature, 2025.
National Category
Infectious Medicine Microbiology in the Medical Area
Identifiers
URN: urn:nbn:se:umu:diva-244874DOI: 10.1038/s41586-025-09500-2Scopus ID: 2-s2.0-105016879708OAI: oai:DiVA.org:umu-244874DiVA, id: diva2:2002830
Funder
NIH (National Institutes of Health), R01AI132633; R01AI165932; R01AI174584; R21AI182834Marianne and Marcus Wallenberg FoundationRegion StockholmSwedish Research Council, 2020-06249Swedish Research Council, 2021-06602Swedish Research Council, 2020-06224Karolinska InstituteAvailable from: 2025-10-02 Created: 2025-10-02 Last updated: 2025-10-02

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textScopus

Authority records

Rosendal, EbbaÖverby, Anna K.

Search in DiVA

By author/editor
Rosendal, EbbaÖverby, Anna K.
By organisation
Molecular Infection Medicine Sweden (MIMS)Department of Clinical Microbiology
In the same journal
Nature
Infectious MedicineMicrobiology in the Medical Area

Search outside of DiVA

GoogleGoogle Scholar

doi
urn-nbn

Altmetric score

doi
urn-nbn
Total: 29 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf